Introduction {#Sec1}
============

Community-acquired pneumonia (CAP) remains a significant cause of morbidity and mortality, resulting in an estimated 1.5 million adult hospitalizations annually in the United States \[[@CR1]•, [@CR2]\]. Despite advances in sepsis recognition and management and being a core measure by the Centers for Medicare & Medicaid Services, the in-hospital mortality of patients admitted with CAP remains high at 6.5% with all-cause mortality at 30 days, 6 months, and 1 year estimated to be 13%, 23%, and 31%, respectively \[[@CR1]•, [@CR3]\]. The broad spectrum of pathogens causing CAP remains unchanged and includes typical bacteria (*Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*), atypical bacteria (*Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, *Legionella spp.*), viruses (such as rhinovirus, influenza, parainfluenza*,* respiratory syncytial virus, coronaviruses, human metapneumovirus) and less frequently *Staphylococcus aureus*, gram-negative bacilli, fungi, and mycobacteria \[[@CR4]\]. While diagnostic techniques to facilitate the accurate identification of causative agents have improved, including the rapid evolution of commercial multiplex PCR assays, an etiologic agent is identified in fewer than half of CAP cases and frequently leaves clinicians to rely on empiric antimicrobials for management \[[@CR5], [@CR6]•\].

Mechanism of Action {#Sec2}
===================

Macrolide antimicrobials are commonly prescribed agents for the management of respiratory tract infections \[[@CR7]\]. As a class, macrolides are bacteriostatic and function by inhibiting bacterial protein synthesis through reversible binding to 23S ribosomal RNA of the 50S ribosomal subunit, resulting in inhibition of RNA-dependent protein synthesis \[[@CR8]\].

However, widespread resistance to macrolides due to point mutations in the 23S rRNA binding site has significantly limited their utility \[[@CR9], [@CR10]\]. *S. pneumoniae* resistance to macrolides has demonstrated regional variability with rates ranging from 30% in North America to over 90% in Vietnam while *M. pneumoniae* demonstrates similar resistance ranging from 10% in the United States to over 90% in regions of Japan \[[@CR11]--[@CR14]\].

Aside from antimicrobial properties, macrolides are also prescribed for their immune modulating effects, particularly in the setting of chronic inflammatory lung diseases. Macrolides have been shown to suppress pro-inflammatory cytokines \[[@CR15]\], decrease polymorphonuclear cell recruitment \[[@CR16]\], attenuate reactive oxygen species \[[@CR17]\], and alter key transcription factors \[[@CR18]\]. While several small studies have shown that immune modulation from macrolides may also be beneficial in acute CAP by reducing inflammatory mediators, supportive research linked to clinical outcomes remains limited and a clear benefit has not been established \[[@CR19], [@CR20]\].

CAP Microbiology {#Sec3}
================

A recent effort to characterize causative CAP pathogens through the use of modern diagnostic tests has been published in the Center for Disease Control and Prevention (CDC) Etiology of Pneumonia in the Community (EPIC) study \[[@CR6]•\]. The CDC EPIC study was a prospective, multicenter, population-based active surveillance study of 2320 patients with radiographically confirmed pneumonia at five US hospitals between 2010 and 2012. In addition to conventional diagnostic tests, extensive molecular and serologic testing was employed to characterize causative pathogens. In this cohort, human rhinovirus, influenza, and *S. pneumoniae* were the most common etiologic agents. Atypical pathogens were infrequently identified---with the incidence of *M. pneumoniae*, *C. pneumoniae*, and *L. pneumophila* each representing less than 0.5 cases per 10,000 adults in the community. This study provides contemporary, comprehensive microbiologic CAP data that is essential in informing guidelines and choosing empiric therapies wisely. The low incidence of atypical pathogens is of particular interest.

Clinical Practice Guideline Recommendations {#Sec4}
===========================================

Published recommendations regarding the use of beta-lactams in combination with macrolides in current clinical practice guidelines are variable and based on relatively low quality evidence that is frequently retrospective, observational, and heterogeneous in nature. Last updated in 2007, the joint Infectious Disease Society of America (IDSA)/American Thoracic Society (ATS) guidelines for CAP recommend empiric combination therapy with a beta-lactam plus macrolide or monotherapy with a respiratory fluoroquinolone (e.g., moxifloxacin) for adult patients hospitalized with CAP in a non-ICU setting \[[@CR21]\]. Combination therapy is recommended for all patients with severe CAP (inpatient ICU). In contrast, guidelines published by the British Thoracic Society (BTS, 2009) and National Institute for Health and Care Excellence (NICE, 2014) recommend beta-lactam monotherapy for low-severity CAP with consideration of combination therapy only in moderate to severe CAP \[[@CR22], [@CR23]\].

Rationale for the Use of Macrolides {#Sec5}
===================================

The body of evidence used to support current IDSA/ATS guideline recommendations that advocate for combination therapy with a beta-lactam plus macrolide in the management of hospitalized adult patients with CAP originates from a series of large, retrospective cohort studies that showed improved clinical outcomes in patients treated with combination therapy.

Gleason et al. evaluated the relationship between initial antimicrobial therapy and clinical outcomes in a retrospective cohort of 12,945 Medicare patients hospitalized with pneumonia \[[@CR24]\]. Thirty-day mortality was lower when a macrolide was combined with a second-generation cephalosporin (HR, 0.71; 95% CI, 0.52--0.96) or third-generation cephalosporin (HR, 0.74; 95% CI, 0.60--0.92) compared to conventional beta-lactam monotherapy. Houck et al. similarly evaluated a retrospective cohort of Medicare patients hospitalized with pneumonia in 10 western states during the years 1993, 1995, and 1997 \[[@CR25]\]. Therapy with a macrolide in combination with a beta-lactam was associated with a significant reduction in mortality (aOR, 0.42; 95% CI, 0.25--0.69) in 1993 but this effect was not observed during the other years of study. Dudas et al. subsequently performed a prospective, observational cohort study at 72 community hospitals to evaluate compliance with ATS guidelines in patients with non-severe community-acquired pneumonia and compared outcomes between patients administered varying combinations of antimicrobials \[[@CR26]\]. Compliance with ATS guidelines was found to be 81% and the addition of a macrolide to a beta-lactam was associated with decreased mortality and reduced length of hospital stay. Brown et al. further reinforced these findings by evaluating a retrospective cohort of 44,814 patients in a hospital claims database \[[@CR27]\]. In this cohort, macrolide combination therapy was associated with decreased mortality, length of hospital stay, and healthcare-associated costs overall.

Based on the findings of these large observational studies, many clinical practice guidelines recommend combination therapy with a beta-lactam plus macrolide or monotherapy with a respiratory fluoroquinolone as first-line therapy for hospitalized adult patients with CAP. However, this recommendation for routine combination therapy for the management of CAP has remained a contentious issue.

Despite the body of (predominantly retrospective, observational) evidence that demonstrates improved clinical outcomes, many clinicians regard this evidence (which grounds guideline recommendations) to be low quality and have called for further prospective, randomized-controlled trials to address this question. The routine use of macrolides in hospitalized adults to augment the spectrum of antimicrobial coverage in mild to moderate CAP patients to include atypical pathogens has been questioned owing to the infrequent identification of these pathogens. *M. pneumoniae* and *C. pneumoniae* are also specifically known for producing relatively mild illness with minimal existing literature that targeted antibiotic therapy impacts patient mortality \[[@CR28]\]. Additionally, any adjunctive benefit from the postulated anti-inflammatory effect of macrolides in the treatment of CAP remains unproven. Given the increasing resistance of *S. pneumoniae* and *M. pneumoniae* isolates to macrolide antibiotics, unnecessary exposure to potential harms associated with macrolide use (potential cardiotoxicity, *Clostridium difficile* infection, etc.), and the economic costs of unnecessary combination therapy, many have called the routine use of combination beta-lactams plus macrolides into question \[[@CR29]--[@CR33]\].

Additional studies have attempted to bring clarity to this controversy. A systematic review and meta-analysis performed by the Cochrane Acute Respiratory Infections Group explored if the addition of atypical coverage to an antimicrobial regimen would improve patient outcomes \[[@CR34]\]. In 28 trials, including 5939 patients hospitalized with CAP, there was no overall difference in mortality (RR 1.14, 95% CI: 0.84--1.55) between the atypical and the typical coverage arms. A trend towards fewer clinical failures was observed in the atypical therapy arm, but this did not achieve statistical significance (RR 0.93; 95% CI: 0.84--1.04). Of note, the Cochrane Review only included one study that specifically focused on the comparison of beta-lactam monotherapy to beta-lactam/macrolide combination therapy. Asadi et al. also compared macrolides to other treatment regimens in adults hospitalized with CAP in a systematic review and meta-analysis including 23 studies and 137,574 patients \[[@CR35]\]. While overall macrolide use was associated with a statistically significant reduction in mortality when compared to non-macrolide use, the survival advantage disappeared (4.6 vs 4.1%; RR 1.13; 95% CI: 0.65--1.98) when analyses were restricted to RCTs.

Randomized Trials {#Sec6}
=================

In recent years, researchers have attempted to address the paucity of high-quality evidence with several prospective, randomized-controlled trials aimed at evaluating the utility of combination antimicrobial therapy in hospitalized adults with CAP.

Garin et al. tested the non-inferiority of beta-lactam monotherapy compared with beta-lactam/macrolide combination therapy in moderately severe patients with CAP in an open-label, multicenter, non-inferiority randomized control trial \[[@CR36]••\]. The study was conducted in six acute care hospitals in Switzerland from 2009 to 2013. The primary endpoint in this trial was the proportion of patients not achieving clinical stability at day 7. After 7 days of therapy, 41% in the monotherapy arm and 33% in the combination arm had not reached clinical stability (7% difference, *p* = 0.07), exceeding the predefined non-inferiority boundary. Patients identified to have atypical pathogens or severe pneumonia (PSI ≥ 4) were less likely to reach clinical stability with monotherapy while patients infected with typical pathogens or mild to moderate CAP severity (PSI 1 to 3) had equivalent outcomes. Secondary endpoints that included overall mortality, need for ICU admission, complications, length of stay, and recurrence of pneumonia within 90 days did not differ significantly between the two groups.

Postma et al. designed the CAP-START Trial, a multi-center cluster-randomized, crossover, non-inferiority trial conducted at 7 hospitals in the Netherlands to determine if empiric therapy for CAP with beta-lactam monotherapy was non-inferior to combination beta-lactam/macrolide therapy or a respiratory fluoroquinolone \[[@CR37]••\]. Adult patients were included if they demonstrated radiographic evidence of pneumonia and compatible clinical findings. Patients were excluded if they had cystic fibrosis, positive Legionella antigen, recent hospitalization, or were from a long-term care facility. The unadjusted 90-day all-cause mortality was 9.0% (beta-lactam monotherapy), 8.8% (FQ monotherapy), and 11.1% (beta-lactam/macrolide combination). Adjusted comparisons for 90-day all-cause mortality favored beta-lactam monotherapy with a 1.9% lower risk of death when compared to macrolide combination therapy (90% CI: −0.6 to 4.4). Time to oral antibiotic de-escalation, length of hospital stay, and occurrence of complications during hospital stay were not significantly different between the groups. While criticisms of this study included a high rate of protocol deviation in the beta-lactam monotherapy group to include atypical coverage, subgroup analyses of strategy-adherent and antibiotic-adherent groups revealed no significant difference in outcomes.

Van Werkhoven et al. further evaluated outcomes in a subset of 179 patients from the CAP-START Trial that had previous beta-lactam exposure prior to hospitalization \[[@CR38]••\]. Thirty-day mortality, hospital length of stay, and frequency of treatment escalations were compared between patients that were continued on beta-lactam monotherapy and patients that received beta-lactams and atypical coverage. Despite the beta-lactam monotherapy group being older, having more medical comorbidities, and longer duration of symptoms prior to admission, the authors found no significant differences between groups with respect to 30-day mortality and hospital length of stay.

While these recent trials performed by Garin, Postma, and van Werkhoven provide evidence to support a strategy of beta-lactam monotherapy for patients presenting with mild to moderate CAP, the role of combination beta-lactam/macrolide therapy in critically ill patients with severe CAP remains unclear.

Severe CAP {#Sec7}
==========

The use of macrolide combination therapy in severe CAP is endorsed in various clinical guidelines (Table [1](#Tab1){ref-type="table"}). Again, however, the data to support macrolide use is of relatively low quality and does not clearly explain whether improved outcomes in this population are derived from the antimicrobial or immune-modulatory properties of these agents.Table 1Clinical practice guideline recommendations for empiric management of CAP in hospitalized adult patients (Immunocompetent)IDSA/ATS (2007)BTS (2009)NICE (2014)Mild CAPRespiratory fluoroquinolone or β-lactam plus macrolideβ-lactam monotherapy (amoxicillin preferred)β-lactam monotherapy (amoxicillin preferred)Moderate CAPRespiratory fluoroquinolone or β-lactam plus macrolideβ-lactam plus macrolide or doxycycline or respiratory fluoroquinoloneβ-lactam plus macrolide (amoxicillin preferred)Severe CAPβ-lactam plus macrolide or respiratory fluoroquinoloneβ-lactam plus macrolideβ-lactam plus macrolide (β-lactamase stable agent)

Baddour et al. previously evaluated the impact of combination antibiotic therapy on 844 adult patients with severe bacteremic pneumococcal pneumonia in a prospective, observational multicenter study \[[@CR39]\]. While overall 14-day mortality did not differ significantly in this cohort, combination therapy was associated with significantly reduced mortality among a subset of critically ill patients (23.4 vs 55.3%, *p* \< 0.01) regardless of nationality, level of ICU support, class of antibiotics, and in vitro activity of the prescribed antibiotics. While this study was not limited to combination macrolide therapy, beta-lactam/macrolide therapy remained the most common regimen in the study population.

Multiple retrospective cohort studies have shown a similar effect in critically ill patients with severe pneumococcal pneumonia complicated by bacteremia \[[@CR40]\]. In addition, Sligl et al. explored the impact of beta-lactam/macrolide combination therapy in critically ill patients in a systematic review and meta-analysis involving nearly 10,000 critically ill patients from 28 observational studies and found that combination therapy including macrolides was associated with a significant reduction in mortality \[[@CR41]\]. A subgroup analysis of the cohort evaluated by Garin et al. also supports this literature---demonstrating that patients with severe pneumonia were less likely to achieve clinical stability with beta-lactam monotherapy.

Despite the lack of randomized trials in severe CAP, the available evidence is consistent with current recommendations published in the joint IDSA/ATS guidelines for management of CAP in patients requiring ICU admission. Further research to characterize the potential immune-modulatory effects of macrolides in patients with severe CAP is warranted, specifically because this population is more likely to have concomitant sepsis and deleterious systemic inflammation.

Conclusions {#Sec8}
===========

The utility of macrolide combination therapy in the management of CAP has been a source of significant controversy with a large body of conflicting evidence. Considering the increasing resistance of typical bacterial isolates (specifically *S. pneumoniae*) to macrolides and the infrequent identification of atypical pathogens as causative agents of pneumonia, clinicians need to carefully consider the utility of macrolides in the treatment of CAP. In addition, clinicians need to balance any potential incremental benefit from the anti-inflammatory effect that macrolides may possess against the urgent need for antimicrobial stewardship and responsible antibiotic use.

While population-based epidemiologic studies have historically suggested a benefit of adjunctive macrolides in the management of CAP, most of these studies are of relatively low quality. Emerging evidence from several prospective studies has challenged this practice by failing to show a significant improvement in relevant clinical outcomes in patients hospitalized with mild to moderate CAP. While existing evidence still supports the use of combination therapy in critically ill patients with severe CAP, further randomized-controlled trials are urgently needed to clarify the role of combination therapy in this population. In particular, the potential immune modulatory effect of macrolides in sepsis remains an area of uncertainty.

Based on the current literature, we suggest a pragmatic approach pending further high quality evidence to guide therapy. For patients with mild-moderate CAP requiring hospitalization, we suggest treatment with beta-lactam monotherapy (e.g., ceftriaxone) or a respiratory fluoroquinolone (e.g., moxifloxacin). For patients with severe pneumonia or those requiring ICU-level care, we suggest beta-lactam/macrolide (e.g., ceftriaxone/azithromycin) combination therapy. Empiric therapies, however, may differ based on local epidemiology and antimicrobial susceptibility patterns in each individual health region or institution.
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